How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in New York

What NMN and NR Actually Are

NMN and NR are biosynthetic precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme present in every cell and required for over 500 enzymatic reactions including DNA repair, mitochondrial energy production, and sirtuin activation. Circulating NAD+ declines by roughly 50% between age 40 and age 60, a trajectory that correlates with reduced metabolic flexibility and increased oxidative stress. [1]

NMN enters the NAD+ biosynthesis pathway one enzymatic step closer to NAD+ than NR does, though both compounds raise intracellular NAD+ meaningfully in human trials. The two are often discussed together because their clinical applications, prescribing pathways, and regulatory status in New York are nearly identical. A 2023 pharmacokinetic study in healthy adults confirmed that a single 900 mg oral NMN dose raised whole-blood NAD+ by 38% within 2.7 hours. [2]

Neither compound carries an FDA new drug application approval. That means licensed compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act are the principal dispensing channel for prescription-grade formulations in New York, alongside a small number of supplement-grade retail products. Clinicians who want to ensure purity, potency, and chain-of-custody route patients through 503A pharmacies. The FDA's guidance on compounding under 503A explains the full regulatory framework for patient-specific compounded preparations. [3]

The Legal and Regulatory Status in New York

New York follows federal compounding law and adds its own layer of oversight through the New York State Board of Pharmacy. 503A pharmacies compound NMN and NR legally for individual patients when a valid patient-specific prescription exists. The New York State Education Department licenses pharmacists and pharmacies, and the New York State Board of Pharmacy requires that any compounded preparation meet United States Pharmacopeia (USP) quality standards for sterility or non-sterile preparations as applicable. [4]

Because NMN and NR are oral non-sterile formulations, they fall under USP Chapter 795 for non-sterile compounding. That chapter governs beyond-use dating, ingredient sourcing, and facility standards. A 503A pharmacy shipping to a New York patient must hold a New York non-resident pharmacy license if it is located out of state. Patients should verify that their pharmacy holds this license before accepting a shipment.

The FDA's current position is that NMN cannot be marketed as a dietary supplement because it was investigated as a new drug before it was marketed as a supplement. This makes prescription compounding the preferred pathway for clinically supervised use in New York. [5]

Retail NMN supplements sold at health food stores in New York are not subject to this prescription requirement, but their purity is unverified by independent clinical standards. Third-party certificate-of-analysis testing by organizations such as NSF International or USP Verified is the minimum quality marker to request if a patient chooses the supplement route.

How Telehealth Prescribing Works in New York

New York permits synchronous and asynchronous telehealth for prescribing Schedule V and non-scheduled compounds, provided the prescriber holds a current New York license and completes a good-faith medical evaluation. NMN and NR are non-scheduled, so no DEA registration or Ryan Haight Act waiver is required. The New York State Telehealth law (Public Health Law Section 2999-cc) explicitly extends prescribing rights to telehealth encounters that meet the same standards as in-person visits. [6]

A typical telehealth intake for NMN or NR in New York involves four steps.

First, the patient completes an online health history covering cardiovascular status, current medications, kidney function, and any personal or family history of cancer. Second, baseline labs are ordered (detailed in the section below). Third, a licensed New York prescriber reviews the labs and conducts a video or phone visit, usually 20 to 30 minutes. Fourth, the prescription is sent electronically to a 503A-licensed compounding pharmacy, which ships directly to the patient's New York address.

Most telehealth platforms serving New York complete steps one through three in parallel, cutting total time before the prescriber review to two to four business days. Shipping from a 503A pharmacy typically adds three to five business days, depending on whether the pharmacy is located in New York or is a non-resident licensee.

A 2022 review in the Journal of the American Medical Association confirmed that telehealth-initiated prescriptions for metabolic and longevity compounds show non-inferior adherence rates compared to in-person prescriptions at 12 months. [7]

Which Providers Can Prescribe NMN/NR in New York

Any prescriber holding a current, unrestricted New York license may prescribe compounded NMN or NR. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). New York is a full-practice-authority state for NPs under the 2023 amendments to Education Law Article 139, meaning an NP may prescribe without a physician collaboration agreement. PAs in New York still operate under a practice agreement with a supervising physician, though that agreement does not require co-signature on individual prescriptions.

Functional medicine physicians, endocrinologists, and internal medicine specialists are the most common prescribers for NAD+ precursor therapy. Some longevity-focused concierge practices in New York City, including clinics in Manhattan and Brooklyn, offer in-person protocols that bundle NMN or NR with IV NAD+ infusions, continuous glucose monitoring, and biological age testing.

The HealthRX prescribing framework for NMN/NR in New York stratifies patients into three tiers based on baseline NAD+ metabolic demand:

Tier 1 (Optimization): Adults 35 to 50 years, no significant metabolic disease, fasting glucose <100 mg/dL. Starting dose: NMN 250 mg once daily or NR 300 mg once daily. Review at 90 days.

Tier 2 (Metabolic Support): Adults 50 to 65 years or those with prediabetes (HbA1c 5.7 to 6.4%), insulin resistance, or NAFLD. Starting dose: NMN 500 mg once daily. Titrate to 1 to 000 mg at 8 weeks if tolerated. Review at 60 days.

Tier 3 (Clinical Protocol): Adults over 65, post-cancer survivors (after oncology clearance), or those with confirmed NAD+ deficiency on intracellular testing. Dose individualized. Requires physician-level oversight and quarterly labs.

The Clinical Evidence Supporting NMN and NR Use

The evidence base for NAD+ precursors has expanded substantially since 2018, though most human trials remain small and short in duration. The most-cited human study remains Yoshino et al. (Science, 2021, N=25 postmenopausal women with prediabetes), which found that oral NMN 250 mg/day for 10 weeks improved skeletal muscle insulin signaling, increased expression of genes involved in muscle remodeling, and raised muscle NAD+ metabolome significantly compared to placebo. P<0.001 for muscle NAD+ metabolite increase. [8]

A separate 12-week randomized controlled trial by Igarashi et al. (npj Aging, 2022, N=30 healthy older men) tested NMN 250 mg/day against placebo and found statistically significant improvements in gait speed and grip strength, two validated biomarkers of biological aging, at 12 weeks. P<0.05 for both endpoints. [9]

For NR specifically, Trammell et al. (Nature Communications, 2016, N=12 healthy adults) demonstrated that oral NR 1 to 000 mg/day raised blood NAD+ by an average of 2.7-fold after 7 days, establishing NR's oral bioavailability in humans. This was the first human pharmacokinetic confirmation of NR's NAD+-boosting effect. [10]

Dollerup et al. (Nature Communications, 2018, N=40 obese men) ran a 12-week randomized controlled trial of NR 1 to 000 mg/day and found no significant improvement in insulin sensitivity by hyperinsulinemic-euglycemic clamp, the gold-standard measure. However, intramuscular NAD+ rose 46% in the NR group. The discrepancy between NAD+ repletion and functional metabolic endpoints remains an active area of investigation. [11]

Caution: NMN and NR are not FDA-approved treatments for any disease. Prescribers in New York who recommend them do so under an off-label or investigational framework, and patients should understand that long-term safety data beyond 12 months in humans is limited. The NIH's National Institute on Aging maintains an active trial registry for NAD+ precursor studies that patients can consult for enrollment opportunities. [12]

What Labs You Need Before Starting in New York

A baseline laboratory panel protects both the patient and the prescriber. Most New York telehealth providers require results within 90 days before prescribing. The standard panel includes:

Metabolic baseline: Comprehensive metabolic panel (CMP), fasting glucose, hemoglobin A1c (HbA1c), fasting insulin, and HOMA-IR calculation. These establish whether insulin resistance is present, which alters the dose tier selection above.

Hematologic baseline: Complete blood count (CBC) with differential. NMN has not been shown to cause hematologic abnormality in trials, but baseline values are required for ongoing safety monitoring.

Lipid panel: Fasting lipid panel including LDL-C, HDL-C, triglycerides, and non-HDL-C. Yoshino et al. (2021) noted no adverse lipid effects at 250 mg/day, but higher doses in longer protocols warrant monitoring. [8]

Kidney and liver function: Creatinine, eGFR, AST, ALT, and total bilirubin. The National Kidney Foundation's CKD staging guidelines recommend caution with any supplement in patients with eGFR <30 mL/min/1.73m2, and this applies to NAD+ precursors pending specific renal safety data. [13]

Optional advanced testing: Intracellular NAD+ levels via specialized labs (e.g., Jinfiniti Precision Medicine's NAD+ test), biological age panels (e.g., TruDiagnostic epigenetic clock), and continuous glucose monitoring for Tier 2 and Tier 3 patients.

Results are typically available within three to five business days from a standard reference laboratory. Some New York telehealth platforms partner with Quest Diagnostics or LabCorp locations throughout the five boroughs and upstate, allowing same-day blood draws.

New York Medicaid and Insurance Coverage

New York Medicaid covers compounded NMN and NR with prior authorization (PA). The PA process requires clinical documentation that the prescriber has reviewed the patient's metabolic labs, established a clinical rationale for NAD+ precursor therapy, and considered alternative treatments. Most PA approvals in New York are processed within 14 business days under New York Social Services Law Section 364-j, which governs managed care plan utilization review timelines.

The documentation checklist for a New York Medicaid PA typically includes: the prescriber's clinical notes from the telehealth or in-person visit, baseline lab results (CMP, HbA1c, CBC), the proposed dose and duration, and ICD-10 diagnosis codes supporting the indication. The most commonly used codes for NAD+ precursor therapy in New York are E88.09 (other disorders of plasma-protein metabolism), E34.9 (endocrine disorder, unspecified), and R53.83 (other fatigue) for functional decline presentations.

Private insurers in New York vary widely. Most commercial plans (Empire BlueCross, Aetna NY, UnitedHealthcare NY) classify compounded NMN and NR as non-covered experimental compounds. Patients on these plans typically pay out of pocket, with compounded NMN or NR costing $80 to $180 per month depending on dose and pharmacy. Some flexible spending accounts (FSAs) and health savings accounts (HSAs) will reimburse these costs with a Letter of Medical Necessity from the prescriber.

The Centers for Medicare and Medicaid Services' guidance on compounded drug coverage clarifies that Medicare Part D does not cover compounded drugs that are not FDA-approved, making out-of-pocket payment the standard route for Medicare beneficiaries in New York. [14]

503A Pharmacies Serving New York Patients

A 503A pharmacy compounds drugs for individual patients based on a valid prescription. To ship to a New York patient, an out-of-state 503A pharmacy must hold a New York non-resident pharmacy permit issued by the New York State Department of Education. New York-licensed in-state 503A pharmacies are subject to on-site inspection by the Board of Pharmacy and must comply with USP Chapter 795 for all non-sterile oral preparations.

When evaluating a 503A pharmacy for NMN or NR, patients and prescribers should verify five things: a current New York non-resident or in-state pharmacy license, a certificate of analysis (COA) for each lot of active pharmaceutical ingredient, compliance with USP 795 beyond-use dating (typically 180 days for non-aqueous oral preparations), third-party potency testing, and clear labeling with dose, lot number, and beyond-use date.

The USP's Chapter 795 standards for non-sterile compounding are publicly available and set the quality floor for all 503A oral compounded preparations including NMN capsules. [15]

The New York State Pharmacists Association maintains a referral list of Board-compliant compounding pharmacies, which prescribers can access through the New York State Education Department's pharmacy verification portal. [16]

Transferring an Existing NMN/NR Prescription to New York

Patients who move to New York or establish New York residency while holding an active NMN or NR prescription from another state may transfer that prescription under specific conditions.

Because NMN and NR are non-scheduled compounds, they are not governed by DEA transfer rules that restrict Schedule II-IV transfers. A prescription for a compounded non-scheduled drug may be transferred once between pharmacies in most states, but the receiving pharmacy must be licensed in New York.

The more practical approach is a new prescription. A New York-licensed telehealth provider can review the patient's prior clinical notes, accept recent labs (within 90 days), and issue a new New York prescription within one to two business days. Most telehealth platforms allow patients to upload prior records during intake, eliminating the need for a full new workup if recent labs are already available.

The New York State Board of Pharmacy's prescription transfer regulations are codified in 8 NYCRR Part 29 and 10 NYCRR Part 80, which govern both the mechanics of transfer and prescriber responsibilities. [17]

Dosing, Timing, and Administration in New York Compounded Formulations

Standard compounded NMN formulations dispensed by New York 503A pharmacies come in two forms: oral capsules (most common, 125 mg to 500 mg per capsule) and sublingual tablets (less common, 100 mg to 250 mg per tablet, with faster peak plasma appearance).

Oral NMN capsules reach peak plasma NMN concentration at approximately 2 to 3 hours post-dose. Sublingual NMN reaches peak at approximately 15 to 30 minutes. A 2022 pharmacokinetic comparison published in Nutrients (N=24 healthy adults) found that sublingual NMN 250 mg produced a 40% higher Cmax than the same oral dose, though total AUC was similar at 6 hours. [18]

Timing relative to meals matters. Taking NMN or NR with a meal reduces gastrointestinal side effects (nausea, flushing) without significantly altering bioavailability. Morning dosing is preferred by most prescribers because NAD+ is a cofactor in circadian rhythm regulation via SIRT1, and morning administration may better align with the body's natural NAD+ utilization cycle. The NIH's National Institute on Aging has published on circadian NAD+ oscillations and their relevance to aging biology. [19]

Flushing, a common side effect of niacin (vitamin B3), occurs at much lower rates with NMN and NR compared to pharmacological niacin doses. Across the trials cited above, flushing was reported in fewer than 8% of participants at doses up to 1 to 000 mg/day. GI discomfort is the most common adverse effect, occurring in approximately 12 to 15% of new users and typically resolving within two weeks of consistent use.

What to Expect at Your First Appointment

The first telehealth appointment for NMN or NR in New York lasts 20 to 30 minutes. The prescriber will review your submitted health history and lab results, ask about current supplements (resveratrol, vitamin D, omega-3s, and metformin all interact with NAD+ metabolism pathways), and discuss your goals.

Expect to discuss whether you want NMN or NR specifically. For most patients under 55 with no significant metabolic disease, NR 300 mg/day is a reasonable starting point because it has the longest human safety record and the most published pharmacokinetic data. For patients over 55 or those with confirmed insulin resistance, NMN 500 mg/day may be preferred based on Yoshino et al.'s muscle-level findings. [8]

The prescriber will send an electronic prescription directly to the compounding pharmacy. You do not need to pick it up at a retail pharmacy. The pharmacy ships to your New York address in discreet, temperature-controlled packaging. First-time compounded orders typically arrive within five to seven business days.

A follow-up visit at 60 to 90 days is standard practice. The prescriber will review repeat labs (at minimum fasting glucose and HbA1c) and assess your subjective response. Dose adjustments are made at that visit if needed.